AndroScience Corporation Selected as a Finalist to Present at 21st Annual CONNECT Financial Forum

Posted in: News & Events
By Press Release
Mar 21, 2005 - 1:15:04 PM

For Immediate Release

AndroScience Corporation Selected as a Finalist to Present at 21st Annual CONNECT Financial Forum

San Diego, March 21, 2005 – AndroScience Corporation today announced that it has been chosen to present at “The 21st Annual CONNECT Financial Forum” on April 14th.

AndroScience ( is one of a select group of high-caliber growth companies invited to participate in the annual conference sponsored by CONNECT, which is widely regarded as the nation's most successful regional program linking very-early-stage high-technology and life science entrepreneurs with the resources they need for success. This premier investment forum provides VC and private-equity investors, institutional and hedge funds, and technology executives an early look at many of the most exciting companies in Southern California.

“We’re delighted to be presenting at this prestigious event, which will attract an estimated 300 high tech and life sciences investors, entrepreneurs, and high-level executives.  This conference gives us high-level exposure to future funding sources as well as potential strategic partnerships,” noted Charles Shih, PhD, CEO and Andrew Loh, PhD, COO of AndroScience Corporation.  “The exposure to blue-chip funding entities is priceless.”

According to Duane Roth, Executive Director of CONNECT, “The CONNECT Financial Forum continues to bridge the gap between promising companies and capital providers. It’s an ideal way for start-ups to get exposure and engage a roomful of venture capitalists and potential investors. In turn, capital providers gain access to pre-screened companies with commercially viable technologies, all in a single day.”

The program will be held on April 14th, 2005 at Sheraton Harbor Island – West Tower, San Diego. For more information on attending or accessing presenting company profiles, please go to
The conference’s sponsors include Morrison & Foerster, IBM, Merck, Roth Capital Partners, Heller Ehrman, Ernest & Young, San Diego Daily Transcript, McQuerter PR, Comerica, Tech Coast Angels, and Knobbe Martens Olson & Bear LLP.

AndroScience, formed in 1999, uses its expertise in natural product chemistry to discover proprietary compounds that target the androgen (male hormones) activation pathway which may be important in acne, alopecia, benign prostatic hyperplasia (BPH), prostate cancer, wound healing, and other diseases. AndroScience has recently discovered and patented a family of compounds derived from natural products that enhance the degradation of the androgen receptor. These compounds selectively enhance androgen receptor degradation, preventing androgen from exerting its unwanted functions on acne and prostate cancer growth.  In addition, these compounds do not affect the endogenous androgens, testosterone or dihydrotestosterone (DHT). This appears to be a novel and unique mechanism of action. They are efficacious both topically and systemically as demonstrated in animal models. An IND is planned and Phase 1 and 2 Clinical Trials for dermal application in acne will be initiated beginning in 2006 and alopecia trials will follow.  Other compounds are being developed for prostate cancer, BPH, and wound healing.


CONNECT is the globally recognized, university-based non-profit organization fostering entrepreneurship in the San Diego region by catalyzing, accelerating, and supporting the growth of the most promising technology and life sciences businesses. Focused on assisting growth companies in the San Diego region, CONNECT has been directly involved with over 900 companies since its inception in 1985, helping them raise over $11B in capital. Part of the University of California, San Diego, CONNECT has a dual role in accelerating growth: it assists growth companies in the San Diego region and promotes the commercialization of technology from university-based research. CONNECT's programs also help business service providers, attorneys, accountants, bankers, investors, and marketing professionals with the knowledge about emerging technologies and access to new business opportunities. CONNECT is entirely self-supporting and receives no funding from the University or the State of California. It is supported by membership dues, course fees, and corporate underwriting for specific programs. For more information, visit


AndroScience Corporation
Andrew Loh PhD, COO & VP Business & Drug Development
858-638-7230, 858-401-0578 (cell)

Greg McQuerter
858.450.0030 x105

Home | Corporate Overview | Product Pipeline | Science & Technology | News & Events | Contact Us | Privacy Policy